



Deric X. Geng, PhD

PARTNER

BOSTON

+ 1 617 526 6026

DERIC.GENG@WILMERHALE.COM

Dr. Geng focuses his practice on various patent prosecution and patent litigation areas, and more specifically on US and foreign patent prosecution, due diligence, prior art and patentability search, freedom to operate analysis, *inter partes* review and patent litigation. Dr. Geng has helped a variety of startup, mid-size and well-established clients in the life sciences sector, including chemical, pharmaceutical, biotechnology, and energy industries, to obtain patent protection in the US and foreign countries. Dr. Geng's practice focus also includes Hatch-Waxman and other patent litigations for leading pharmaceutical companies.

Prior to joining the firm, Dr. Geng was a Research Investigator at the Novartis Institute for Biomedical Research in Cambridge, Massachusetts. His primary research involved discovering drug-like molecules that modulated protein targets and pathways implicated in diabetes and metabolic diseases.

From 2002 to 2004, Dr. Geng was a US Army Breast Cancer Research Foundation Postdoctoral Fellow in Dr. Samuel Danishefsky's laboratory at the Memorial Sloan-Kettering Cancer Center in New York, where he accomplished the total synthesis of anticancer agent aigialomycin D and worked as a part of a team to design and accomplish the total synthesis of fully synthetic gp120 glycopeptides as anti-HIV vaccine agents.

Dr. Geng obtained his PhD degree from State University of New York at Stony Brook in 2002, where he designed and synthesized taxoid and taxane-free anticancer agents in Professor Iwao Ojima's laboratories.

Selected Journal Publications and Patents

- Ojima, I. et al., "Design, synthesis, and biological evaluation of new-generation taxoids," *Journal of Medicinal Chemistry*, 2008, 51, 3203-3221.
- Krauss, I. J. et al, "Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody," *Journal of the American Chemical Society*, 2007, 129, 11042-11044.

- Warren, J.D.; Geng, X.; Danishefsky, S. J., "Synthetic glycopeptides-based vaccines," *Topics in Current Chemistry* 2007, 267 (Glycopeptides and Glycoproteins), 109-141.
- Geng, X.; Danishefsky, S. J. "Total synthesis of aigialomycin D", *Organic Letters* 2004, 6, 413-416.
- Geng, X., Yang, Z.-Q., Danishefsky, S. J. "Synthetic development of radicicol and cycloproparadicicol: highly promising anticancer agents targeting Hsp90", *Synlett* 2004, 8, 1325-1333.
- Geng, X.; Dudkin, V. Y.; Mandal, M.; Danishefsky, S. J. "Glycopeptides (2): In pursuit of carbohydrate-based HIV vaccines, Part 2: the total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence", *Angewandte Chemie International Edition* 2004, 43, 2562-2565.
- Geng, X.; Geney, R.; Pera, P.; Bernacki, R. J.; Ojima, I. "Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton", *Bioorganic Medicinal Chemistry Letters* 2004, 14, 3491-3494.
- Geng, X.; Miller, M. L.; Lin, S.; Ojima, I. "Synthesis of novel C2-C3'N-linked macrocyclic taxoids by means of highly regioselective heck macrocyclization", *Organic Letters* 2003, 5, 3733-3736.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Kraus, I., Gp120 specific antigen and uses thereof, US Patent No. 7,531,181.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Olson, W.; Orlova, M., Preparation of gp120 glycopeptide dimers for treatment of HIV-1, 2006, WO 2006017180.
- Danishefsky, S. J.; Yang, Z.-Q.; Geng, X.; Chou, T.-C.; Rosen, N., Preparation of aigialomycin D, radicicol and monocillin I and their macrocyclic analogs for use in pharmaceutical compositions as antitumor agents, 2005, WO 2005061481.
- Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M., Glycopeptide gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof, 2004, WO 2004050711.

Professional Activities

Dr. Geng is a member of the Boston Patent Law Association.

Solutions

Intellectual Property
Counseling and Prosecution

Life Sciences

Recognition

- Selected for inclusion in *Best Lawyers: Ones to Watch* for intellectual property law in 2023 and 2024.
- Named to *Boston Magazine's* inaugural Top Lawyers list in 2021 in the area of civil litigation/defense and in 2022 and 2023 in the area of intellectual property rights.
- Named a *Massachusetts Super Lawyers* "Rising Star" for IP law (2017–2018 and 2020–2023).
- US Army Breast Cancer Foundation Postdoctoral Fellow.
- SUNYSB President's Award to Distinguished Doctoral Students.

Credentials

EDUCATION

JD, Suffolk University Law School, 2013

summa cum laude

Academic Leadership

Scholarship, 2010-2013; LPS

Distinguished Best Brief Award,

2009-2010; Jurisprudence

Award – Civil Procedure, Spring

2010; Jurisprudence Award –

Constitution Law, Spring 2011;

Jurisprudence Award –

Commercial Law Survey, Fall

2012; Dean's List, 2009-2012

PhD, Chemistry, State University of New York at Stony Brook, 2002

BS, Chemistry, Peking University, 1997

ADMISSIONS

Massachusetts

LANGUAGES

Chinese (Mandarin)